Discovery of Oxidized <i>p</i>-Terphenyls as Phosphodiesterase 4 Inhibitors from Marine-Derived Fungi-Reference-Cited by-同舟云学术

Discovery of Oxidized p-Terphenyls as Phosphodiesterase 4 Inhibitors from Marine-Derived Fungi

Published:2024-06-29 Issue:7 Volume:87 Page:1808-1816
ISSN:0163-3864
Container-title:Journal of Natural Products
language:en
Short-container-title:J. Nat. Prod.

Author:

Cai Jian¹²,Zhou Qian³⁴,Qi Xin⁵,Zhang Furong³⁴,Yang Jiafan¹²^ORCID,Chen Chunmei¹²,Zhang Kai³⁴,Chen Zhexin³⁴,Luo Hai-Bin³⁴,Liu Yonghong¹^ORCID,Huang Yi-You³⁴,Zhou Xuefeng¹²^ORCID

Affiliation:

1. CAS Key Laboratory of Tropical Marine Bio-resources and Ecology/Guangdong Key Laboratory of Marine Materia Medica, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510301, China

2. University of Chinese Academy of Sciences, Beijing 100049, China

3. Key Laboratory of Tropical Biological Resources of Ministry of Education and Hainan Engineering Research Center for Drug Screening and Evaluation, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China

4. Song Li’ Academician Workstation of Hainan University (School of Pharmaceutical Sciences), Yazhou Bay, Sanya 572000, China

5. Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China

Funder

National Key Research and Development Program of China

Basic and Applied Basic Research Foundation of Guangdong Province

Natural Science Foundation of Hainan Province

Hainan University

National Natural Science Foundation of China

Department of Natural Resources of Guangdong Province

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jnatprod.4c00422

Reference27 articles.

1. Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor

2. Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide

3. Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection

4. Ibudilast for the treatment of multiple sclerosis

5. Phase 2, randomized, double‐blind, placebo‐controlled, 4‐week study to evaluate the safety and efficacy of OPA‐ 15406 (difamilast), a new topical selective phosphodiesterase type‐4 inhibitor, in Japanese pediatric patients aged 2–14 years with atopic dermatitis